(Reuters) - Targacept Inc said its experimental Alzheimer's drug did not show superiority over standard medication in a mid-stage study and that it would no longer invest in the development of the treatment. The company's shares were down about 16.44 percent. The drug, TC-1734, was being tested against Pfizer Inc's donepezil. (Reporting By Amrutha Penumudi; Editing by Don Sebastian) via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment